People · Operator
Named in public records as an officer, director or promoter · active 2024–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evogene Ltd. | — | Pharmaceuticals | Series A | $15.4M | $8.4M | 2024 |
Dan Falk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dan Falk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nir Nimrodi | 1 | 2 |
| Adrian Percy | 1 | 2 |
| Gabi Tarcic | 1 | 1 |
| Leon Yehuda Recanati | 1 | 1 |
| Ofer Haviv | 1 | 1 |
| Ilia Zhidkov | 1 | 1 |
| Mark Kapel | 1 | 1 |
| Yaron Eldad | 1 | 1 |
| Eyal Ronen | 1 | 1 |
| Sassi Masliah | 1 | 1 |
| Oded Y. Shoseyov | 1 | 1 |
| Leon Y. Recanati | 1 | 1 |
| Sarit Firon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.